Physician profile
Sara E Ward
NPI 1992376115
$1,740.78
in general payments reported to CMS, 2019-2025
13 companies · $257 in 2025
The $257 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $145 · 2022: $358 · 2023: $432 · 2024: $549 · 2025: $257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,238.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $605.57 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $253.17 | 2023-2025 | Rexulti |
| Daiichi Sankyo INC. | $248.07 | 2021-2022 | |
| Amgen INC. | $104.45 | 2024 | Otezla |
| Teva Pharmaceuticals USA, INC. | $97.81 | 2022-2023 | Austedo |
| Novo Nordisk INC | $97.66 | 2024-2025 | Ozempic |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $79.11 | 2024-2025 | Caplyta |
| Astrazeneca Pharmaceuticals Lp | $61.75 | 2023-2025 | Fasenra, Breztri |
| Lundbeck LLC | $55.54 | 2024-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company Ltd. | $49.28 | 2022 | |
| Axsome Therapeutics, INC. | $46.43 | 2024-2025 | Auvelity |
| Pfizer INC. | $29.90 | 2023 | |
| Corium, LLC | $12.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.